tiprankstipranks
Advertisement
Advertisement
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
PremiumThe FlyPsychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
1M ago
Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety
Premium
Company Announcements
Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety
1M ago
Helus Pharma announces results in Phase 2 signal detection study of HLP004
Premium
The Fly
Helus Pharma announces results in Phase 2 signal detection study of HLP004
1M ago
Psychedelic: Exclusive talk with nonprofit organization MAPS
PremiumThe FlyPsychedelic: Exclusive talk with nonprofit organization MAPS
2M ago
Cybin (Helus Pharma) Names Veteran Pharma Executive Michael Cola as CEO to Drive CNS Growth
Premium
Company Announcements
Cybin (Helus Pharma) Names Veteran Pharma Executive Michael Cola as CEO to Drive CNS Growth
2M ago
Helus Pharma’s Short-Acting Depression Drug Shows Durable Benefit in Phase 2a Trial
Premium
Company Announcements
Helus Pharma’s Short-Acting Depression Drug Shows Durable Benefit in Phase 2a Trial
2M ago
Psychedelic: Clearmind reports additional CMND-100 safety results
PremiumThe FlyPsychedelic: Clearmind reports additional CMND-100 safety results
2M ago
Helus Pharma Taps Industry Veteran Michael Cola as CEO Ahead of Key Trial Milestones
Premium
Company Announcements
Helus Pharma Taps Industry Veteran Michael Cola as CEO Ahead of Key Trial Milestones
2M ago
Helus Pharma appoints Cola as CEO
Premium
The Fly
Helus Pharma appoints Cola as CEO
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100